modern
transfus
medicin
europ
success
handl
major
threat
safe
blood
suppli
classic
viral
transfusiontransmit
pathogen
like
hcv
hiv
howev
manag
util
major
financi
expert
resourc
today
european
harmonis
optim
use
blood
compon
clinic
hemotherapi
uniform
qualiti
standard
blood
donat
test
compon
product
well
increas
cost
pressur
clinic
care
task
need
full
attent
modern
cellular
therapi
regen
medicin
novel
treatment
option
handl
close
cooper
clinician
transfus
medicin
specialist
futur
challeng
compris
proactiv
measur
like
pathogen
inactiv
blood
compon
order
diminish
threat
blood
safeti
emerg
pathogen
adequ
blood
suppli
bear
mind
ongo
age
european
popul
polit
decis
regard
potenti
open
blood
market
europ
opinion
support
european
union
histori
world
war
ii
need
modern
medicin
call
well
organ
blood
donor
servic
european
govern
hand
task
respect
nation
red
cross
organ
increas
demand
blood
compon
encourag
mobil
healthi
popul
donat
blood
becam
one
promin
task
new
organ
last
centuri
age
european
popul
nowaday
demand
great
effort
provid
blood
donat
healthi
volunt
sinc
surgic
procedur
elderli
patient
requir
blood
product
procedur
young
peopl
provid
adequ
amount
safe
blood
compon
vital
modern
societi
europ
remain
decid
whether
import
task
handl
nation
red
cross
organ
hospit
privat
pharmaceut
compani
government
organ
even
possibl
combin
hemophilia
patient
former
time
die
earli
adulthood
due
bleed
complic
introduct
selftreat
home
factor
viii
factor
xi
concentr
help
patient
achiev
normal
life
expect
howev
hemophiliac
treat
suffer
hepat
b
hepat
c
last
decad
last
centuri
last
centuri
first
aid
scandal
help
acceler
develop
heatinactiv
factor
viii
concentr
later
last
centuri
second
aid
scandal
blood
product
shock
germani
follow
public
author
close
paulehrlichinstitut
took
respons
grant
market
author
blood
plasma
product
new
institut
like
arbeitskrei
blut
german
ministri
health
expert
transfus
medicin
hemostaseolog
patient
care
establish
new
law
like
transfus
law
inaugur
well
sinc
safeti
blood
product
becom
one
highest
prioriti
germani
well
european
countri
qualiti
safeti
blood
compon
increas
dramat
sinc
begin
last
centuri
registr
blood
donor
servic
pharmaceut
compani
manufactur
licens
market
author
blood
product
inlin
filtrat
whole
blood
donat
order
diminish
leucocyt
contamin
final
blood
compon
qualiti
control
qualiti
manag
well
inspect
proactiv
measur
reduc
threat
safe
blood
suppli
emerg
pathogen
apart
classic
hepat
virus
hi
viru
bacteria
potenti
transfus
transmit
pathogen
new
threat
emerg
pathogen
develop
last
decad
variant
creutzfeldtjacob
diseas
vcjd
caus
prion
viral
infect
like
sever
acut
respiratori
syndrom
sar
avian
influenza
westnileviru
chikungunya
fever
exampl
emerg
pathogen
see
also
tabl
pose
acut
danger
threat
safe
blood
transfus
classic
viral
pathogen
hepat
virus
hiv
today
almost
neglig
transfus
risk
alreadi
describ
new
threat
emerg
pathogen
requir
constant
hemovigil
acut
decis
regard
new
test
procedur
pathogen
introduct
pathogen
inactiv
measur
blood
product
becom
avail
europ
increas
cost
econom
pressur
european
health
care
system
modern
medicin
europ
deal
age
popul
declin
altruist
blood
donat
face
increas
cost
pressur
health
care
system
europ
time
clinic
hemotherapi
transfus
medicin
deal
background
question
aris
whether
suitabl
establish
smaller
hospitalbas
blood
donor
servic
abl
work
close
hospit
staff
versu
bigger
entiti
work
like
pharmaceut
compani
abl
reduc
cost
economi
scale
research
develop
modern
clinic
transfus
medicin
hemotherapi
essenti
part
today
medicin
close
cooper
scientif
network
industri
clinic
partner
tissu
transplant
cell
therapi
new
field
medicin
vital
futur
field
howev
fund
r
competit
pharmaceut
industri
regard
blood
donor
screen
new
blood
substitut
well
growth
factor
like
erythropoietin
thrombopoietin
provid
exampl
problemat
field
competit
mani
expert
call
trend
bloodless
medicin
howev
evid
true
benefit
bloodless
medicin
lack
growth
factor
like
erythropoietin
show
advers
event
like
potenti
increas
tumor
growth
use
led
mortal
reduct
hope
sever
patient
popul
optim
use
blood
product
worthwhil
goal
aim
howev
risk
undertransfus
patient
taken
account
european
countri
strategi
reduc
allogen
blood
transfus
led
less
advertis
healthi
volunt
blood
donor
final
result
dramat
reduct
blood
donat
endang
blood
suppli
countri
futur
challeng
transfus
medicin
medic
maintain
increas
blood
transfus
safeti
success
contain
transmiss
classic
virus
like
hepat
hiv
transfus
focu
shift
sourc
lower
risk
blood
transfus
safeti
screen
blood
donat
prion
bacteri
screen
especi
platelet
concentr
pathogen
inactiv
blood
product
test
new
emerg
pathogen
exampl
ongo
challeng
transfus
medicin
transplant
medicin
transplant
solid
organ
hematopoiet
stem
cell
requir
complex
diagnost
procedur
logist
hlatest
stem
cell
apheresi
storag
well
new
cell
therapi
like
stem
cell
acut
myocardi
infarct
chronic
heart
diseas
exampl
vast
develop
field
new
blood
product
regen
medicin
hematopoiet
stem
cell
bone
marrow
nowaday
almost
complet
replac
peripher
hematopoiet
stem
cell
obtain
via
apheresi
procedur
umbil
cord
stem
cell
promis
sourc
hematopoiet
stem
cell
also
adult
patient
nowaday
cellular
therapeut
gene
therapi
well
immunotherapi
novel
